Steenbrugge, Jonas http://orcid.org/0000-0002-7763-2888
Vander Elst, Niels http://orcid.org/0000-0001-6289-7288
Demeyere, Kristel
De Wever, Olivier
Sanders, Niek N.
Van Den Broeck, Wim
Ciamporcero, Eric
Perera, Timothy
Meyer, Evelyne
Funding for this research was provided by:
Kom op tegen Kanker (Stand up to Cancer), the Flemish cancer society - Emmanuel van der Schueren research grant
Fonds Wetenschappelijk Onderzoek (G.0621.10)
Article History
Received: 13 August 2020
Accepted: 5 February 2021
First Online: 17 March 2021
Competing interests
: J.S., E.C., T.P., and E.M. have inventorship on a patent priority application regarding OMO-1. E.C. is full-time employee of OCTIMET Oncology NV, Beerse, Belgium. T.P. is a cofounder, owns shares, and has a management consultancy agreement with OCTIMET Oncology NV, Beerse, Belgium. E.M. received a research contractual support from OCTIMET Oncology NV, Beerse, Belgium. The other authors declare no competing interests.